Cytek Biosciences
CTKB
54 hedge funds and large institutions have $744M invested in Cytek Biosciences in 2021 Q3 according to their latest regulatory filings, with 54 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
25.69% more ownership
Funds ownership: 0% → 25.69% (+26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$226M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$206M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$62.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$62.7M |
| 5 |
MGM
Miura Global Management
New York
|
+$49.8M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $5K | +$5.25K | +223 | New |
|
52
Wells Fargo
San Francisco,
California
| $2K | +$1.91K | +81 | New |
|
53
Walleye Capital
New York
| $437 | +$480K | +20,400 | New |
|
|
TCM
54
Tradewinds Capital Management
Bellingham,
Washington
| – | +$47 | +2 | New |
|
CTKB Hedge Fund Activity: Q3 2021 in Review
54 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q3 2021, worth a combined $744M.
Buyers outnumbered sellers: 54 funds opened new CTKB positions and 0 closed out — a net gain of 54 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $226M.
- 54 institutional investors held Cytek Biosciences (CTKB) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $744M of Cytek Biosciences stock for Q3 2021.
- 54 funds opened new Cytek Biosciences positions in Q3 2021 and 0 closed out, a net change of +54 holders.
- The largest Cytek Biosciences buyer in Q3 2021 was RA Capital Management, an estimated $226M added.
Based on aggregated 13F filings for Q3 2021.